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Abstract
RAS proteins require membrane association for their biological activity, making this association a 
logical target for anti-RAS therapeutics. Lipid modification of RAS proteins by a farnesyl 
isoprenoid is an obligate step in that association, and is an enzymatic process. Accordingly, 
farnesyltransferase inhibitors (FTIs) were developed as potential anti-RAS drugs. The lack of 
efficacy of FTIs as anti-cancer drugs was widely seen as indicating that blocking RAS membrane 
association was a flawed approach to cancer treatment. However, a deeper understanding of RAS 
modification and trafficking has revealed that this was an erroneous conclusion. In the presence of 
FTIs, KRAS and NRAS, which are the RAS isoforms most frequently mutated in cancer, become 
substrates for alternative modification, can still associate with membranes, and can still function. 
Thus, FTIs failed not because blocking RAS membrane association is an ineffective approach, but 
because FTIs failed to accomplish that task. Recent findings regarding RAS isoform trafficking 
and the regulation of RAS subcellular localization have rekindled interest in efforts to target these 
processes. In particular, improved understanding of the palmitoylation/depalmitoylation cycle that 
regulates RAS interaction with the plasma membrane, endomembranes and cytosol, and of the 
potential importance of RAS chaperones, have led to new approaches. Efforts to validate and 
target other enzymatically regulated post-translational modifications are also ongoing. In this 
review, we revisit lessons learned, describe the current state of the art, and highlight challenging 
but promising directions to achieve the goal of disrupting RAS membrane association and 
subcellular localization for anti-RAS drug development.
Introduction
The three RAS genes (HRAS, NRAS, KRAS) are the most commonly mutated oncogenes in 
human cancers (1,2). The role of oncogenic RAS proteins as key drivers in both common 
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and uncommon cancers has led to intensive efforts over more than three decades to develop 
therapeutics that target RAS, encompassing both direct and indirect approaches. 
Oncogenically mutated RAS proteins fail to cycle “off” from the active, GTP-bound state to 
the resting GDP-bound state, and thereby accumulate in the “on” configuration. Early direct 
approaches sought to attack this impaired molecular switch. Attempts to identify antagonists 
of GTP-binding or to identify drug-like mimics of the negative regulatory GAP proteins 
have been unsuccessful, although new strategies of stabilizing conformational states may yet 
bear fruit, as discussed elsewhere in this CCR Focus section (3). More recent efforts to 
target specific RAS mutations (e.g., KRAS G12C), to interfere with RAS binding to its 
activator SOS1, and to block association with effectors such as RAF1 have been reviewed 
recently (1,4). The consensus at present is that the most fruitful direction for anti-RAS 
therapeutics in the near future is indirect targeting of RAS signaling via inhibiting its 
downstream effectors, particularly the RAF-MEK-ERK and PI3K-AKT-MTOR kinase 
cascades that have been shown to be critical for RAS driver functions in specific cancers. 
These efforts are discussed elsewhere (1,4,5). Other approaches, such as attempts to identify 
additional targets for co-inhibition with RAS, through synthetic lethality screens or 
metabolic dependencies, are also discussed elsewhere in this CCR Focus section (6,7). Here, 
our focus is on direct targeting of RAS by interfering with its membrane association and 
trafficking. We argue that this approach, while challenging, remains both logical and 
potentially tractable, given information that has emerged over the past few years. Because 
the association of RAS proteins with membranes is absolutely required for their function, 
targeting this requirement can be viewed as the functional equivalent not of turning off the 
defective switch that is oncogenic RAS, but of removing it from the circuit.
CAAX Processing and RAS Membrane Association
The critical need for RAS protein association with cellular membranes has been appreciated 
for decades (8,9). RAS association with the plasma membrane (PM) and with other 
membrane compartments upon which signaling occurs (10,11) is promoted by a well-
described series of post-translational modifications at RAS C-terminal CAAX motifs (Fig. 
1), where C = cysteine, A = (usually) aliphatic amino acids and X = a variable amino acid; 
in RAS, X = S or M (12,13). In the initial and obligate step, a 15-carbon farnesyl 
polyisoprene lipid is added by farnesyltransferase (FTase) to the cysteine of the CAAX 
motif through a stable thioether linkage. Subsequently the AAX amino acids are cleaved off 
by the farnesylcysteine-directed endoprotease, RAS converting CAAX endopeptidase 1, also 
known as RAS converting enzyme 1 (RCE1). The carboxyl group of the now C-terminal 
farnesylcysteine is next methylesterified by isoprenylcysteine carboxylmethyltransferase 
(Icmt) to produce RAS proteins with hydrophobic tails that have affinity for membranes. 
Both RCE1 and ICMT are restricted to the endoplasmic reticulum (14,15), indicating that 
RAS must traffic to the PM through this compartment, and suggesting multiple layers of 
location-based regulation (Fig.2). Each of the enzymes involved in these CAAX processing 
steps has been a target for drug discovery.
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Targeting CAAX Prenylation: FTase and GGTase, Statins
RAS farnesylation by FTase is the first, irreversible and rate-limiting step of CAAX 
processing. As it was quickly determined to be both an obligate modification for oncogenic 
RAS biological activity and a process governed by an enzyme that recognized a simple short 
tetrapeptide CAAX motif, this step was rapidly exploited for inhibition. Both rational drug 
design and library screening were employed in numerous intensive and successful efforts to 
identify FTase inhibitors (FTIs) (16,17). Two of these, lonafarnib and tipifarnib, progressed 
to advanced clinical trials but failed to show efficacy against KRAS-driven cancers (16,17). 
The failure of FTIs, once anticipated to bemagic bullets for RAS-driven cancers, to serve as 
broadly effective anti-RAS drugs led to a widespread misperception that even RAS itself is 
not a good target. However, it is critical to recognize that, in the presence of FTIs, NRAS 
and KRAS, but not HRAS, become substrates for geranylgeranyltransferase I (GGTase I) 
through a process known as alternative prenylation (18,19). This phenomenon was revealed 
only when FTIs became available. Since geranylgeranylated RAS proteins still associate 
with membranes and are still biologically active, FTIs were ineffective despite hitting their 
FTase target. Thus, FTIs failed as anti-RAS drugs not because blocking RAS association 
with membranes is a flawed approach, but rather because FTIs failed to achieve this goal. 
Accordingly, we and others have continued to pursue the RAS modification and trafficking 
pathways as logical targets for potential therapeutics. One potential solution to the problem 
of alternative prenylation might be dual inhibition of FTase and GGTase I (20), either by 
combining individual inhibitors of each enzyme, or by dual specificity inhibitors. Such 
inhibitors have been developed and some have reached the clinic (16,17), but have been 
limited by toxicity (21-23). There are still hopes that a therapeutic window can be found, 
possibly by targeting their delivery to RAS-driven cancer cells (17), where oncogenic RAS 
rendered cytosolic by these agents could sequester effectors and act as dominant negatives 
(24,25).
Because farnesyl pyrophosphate (FPP) is both an intermediate in cholesterol biosynthetic 
pathway and is also used for modification of CAAX proteins, it has long been speculated 
that statins may limit cancer by inhibiting prenylation of RAS or related small GTPases. 
However, due to the differential KMs for squalene synthase versus FTase, cholesterol 
synthesis is 1,000-fold more easily inhibited by loss of FPP than is FTase-mediated 
modification of RAS (26). Consistent with this, only suprapharmacological levels of statins 
block protein prenylation in cell culture (27) and cause mislocalization of RAS (28), 
whereas therapeutic levels do not (28). Moreover, the effects of statins on cell growth are 
RAS-independent (27); nor is there evidence for these effects on RAS in animals 
administered pharmacologically relevant doses. Thus, statins show no promise for use as 
anti-RAS drugs.
Targeting Post-Prenylation CAAX Processing: RCE1 and ICMT
Although it is clear that the post-prenylation CAAX processing enzymes also contribute to 
RAS membrane association, making them potentially attractive targets for drug 
development, there are numerous challenges to overcome before inhibition of either RCE1 
or ICMT can be translated to the clinic. These include uncertainty regarding the 
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requirements for RCE1 and ICMT in oncogenic RAS functions, perplexing results from 
genetic validation studies, lack of understanding of the mechanism of RCE1 CAAX protease 
activity, and difficulties in developing inhibitors of these enzymes that can achieve sufficient 
potency and selectivity to become clinically efficacious drugs. Nevertheless, resolving these 
issues is likely to reveal important facets of RAS biology that may in turn reveal additional 
targets, warranting some discussion here.
RCE1 generates the substrate for ICMT: a prenylcysteine with anα carboxyl group. Thus, 
ICMT can act only after RCE1. The sequential nature of these modifications implies that 
RCE1 deficiency should produce cell biological consequences at least as strong as ICMT 
deficiency, if one assumes that the effects of partial processing are similar for each substrate. 
At present, due to the lack of drug-like potent and selective inhibitors, this can be tested 
genetically but not pharmacologically. These studies reveal significant context-dependence 
of deficiencies in these enzymes. Contrary to initial suppositions, Icmt null mice die earlier 
in gestation than do Rce1 null mice (29,30), and Icmt deficiency completely blocked the 
transformed growth of RAS-transformed rodent fibroblasts whereas Rce1 deficiency had 
modest effects (31). Further, the consequences of genetic loss of Rce1 and Icmt can be both 
opposing and context-dependent. In a mouse model, the same myeloproliferative disease 
driven by oncogenic Kras G12D that was ameliorated by Icmt deficiency (32) was enhanced 
by Rce1 deficiency (33). However, Icmt deficiency accelerated the disease in a mouse model 
of pancreatic cancer driven by Kras G12D (34), due to inhibition of signaling from Notch-1, 
which acts as a tumor suppressor in this model (35). Importantly, Icmt deficiency 
ameliorated Kras-driven disease in other mouse tumor models (M.G. Dalin and M.O. 
Bergo;unpublished results), supporting the context-dependency of ICMT impairment. These 
results suggest that better understanding the biology of CAAX processing will be critical to 
further validation of RCE1 and ICMT as potential drug targets, particularly with respect to 
the indications and populations in which they may be best applied. The complexity inherent 
in the context-dependent roles of RCE1 and ICMT is likely explained by the myriad 
substrates of these enzymes other than RAS, many of which are signaling molecules.
Many drugs fail in development due to cardiac toxicity, which is a demonstrated 
consequence of Rce1 depletion in the heart (36). Similarly, targeted depletion of Rce1 in the 
retina resulted in rapid degeneration of specific photoreceptor cells (37). On the other hand, 
the cleavage of RHOA by the bacterial toxin and cysteine protease YopT requires RCE1 but 
not ICMT (38). Thus, even if they can be developed, RCE1 inhibitors may be more toxic 
overall than ICMT inhibitors. Nevertheless, attempts have been made to develop inhibitors 
of both RCE1 (39) and ICMT (40-42), although each will necessarily also affect alternate 
substrates in addition to RAS. Disappointingly, even the most potent and selective of the 
RCE1 inhibitors have recently been shown to lack mechanism-based activity (43). The anti-
proliferative effects of ICMT inhibitors on RAS-transformed cells may be more compelling 
(41,42); whether they can be converted into pharmacological leads is currently unclear.
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RAS Trafficking: “Second Signals,” the Acylation/Deacylation Cycle, and 
RAS Chaperones
RAS membrane association and trafficking are regulated in a complex manner that has yet 
to be fully unraveled (Fig. 2). This complexity has revealed both additional challenges and 
additional targets for drug discovery. First, in addition to modification of the CAAX 
sequence, RAS PM association requires a proximal “second signal” that is either 
palmitoylation of one (NRAS) or two cysteines (HRAS) or a polybasic stretch of lysine 
residues (KRAS4B) (44,45) to confer additional hydrophobicity or an electrostatic 
interaction with the negatively charged headgroups of the phospholipids at the inner leaflet 
of the PM, respectively (Fig. 1). KRAS4A is unique among the four RAS proteins in 
possessing a dual membrane targeting motif that consists of both a palmitoylated cysteine 
and two short polybasic regions flanking that acylated cysteine (46) (Fig. 1) Second, RAS 
association with membranes is not a one-way street. Instead, RAS proteins undergo a cycle 
of delivery to the PM followed by return to endomembranes for recycling, where they can 
interact with a Golgi-resident palmitoylacyl transferase (47). Depalmitoylation of NRAS and 
HRAS at the PM initiates the recycling process(48,49), whereas KRAS4B dissociation from 
the PM is mediated in part by PKC-catalyzed phosphorylation of serine 181 within the 
polybasic region (50). Third, RAS protein trafficking is also modulated by interactions with 
GDI-like chaperones (51,52) that help to shepherd the lapidated RAS proteins among 
hydrophobic membranes through aqueous cytosol, and within specific PM regions (53). 
Among these chaperones are galectin-1 and-3 that escort HRAS and KRAS4B, respectively 
(54-56), and nucleolin that shepherds NRAS (57,58). Phosphodiesterase-6δ (PDE6δ) has 
been variously proposed to chaperone NRAS (46,59) or nonpalmitoylated HRAS (59), and 
KRAS4B (46,60-62) but not KRAS4A (46). RAS proteins are released from PDE6δ upon 
binding of ARL2/3 to an allosteric site on PDE6δ (63). Each of these interactions is 
potentially a source of targets for anti-RAS drugs, and each has been pursued to varying 
degrees.
Targeting RAS Trafficking by Disrupting Palmitoylation: Protein Acyl 
(Palmitoyl) Transferases
Aside from CAAX-signaled modifications, enzymatic targets in the RAS processing 
pathway include those that regulate the palmitoylation/depalmitoylation cycle. KRAS, the 
predominant RAS gene mutated in human cancers, is expressed in two splice variants. The 
nonpalmitoylated KRAS4B has been generally accepted to be the major driver of cancer. 
However, recent work implicating the palmitoylated splice variant KRAS4A in colorectal 
adenocarcinoma (46) may force a re-evaluation of the notion that palmitoylation is not a 
good target in RAS-driven cancers. Moreover, palmitoylation inhibitors may help to limit 
the activity of oncogenic NRAS (64,65), a key driver of melanoma and hematopoietic 
malignancies. As inhibitors of palmitoylation and depalmitoylation are developed, it may 
also be important to better understand the roles of palmitoylated wild type RAS isoforms in 
supporting or impairing oncogenic RAS-driven cancers (1). Nonspecific inhibitors of protein 
palmitoylation such as 2-bromopalmitate (66) have been useful as tool compounds, but are 
unlikely to be developed into drugs given the vast number of palmitoylated proteins in the 
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human genome (67). The recent identification of 23 DHHC (aspartic acid-histidine-
histidine-cysteine tetrapeptide motif) proteins in the mammalian repertoire of protein 
acyltransferases (PATs) supports the feasibility of developing palmitoylation inhibitors that 
are specific for a subset of substrates such as RAS proteins (68). Consensus motifs to link 
specific palmitoylated substrates with their respective PATs have not yet been determined, 
but identification of the DHHC9/GPC16 complex as the PAT that modifies NRAS and 
HRAS (47) suggests the possibility of targeting this process selectively. Although progress 
in this direction has been limited to date (66,68,69), the recent advent of metabolic labeling 
with the bioorthogonal fatty acid 17-octadecynoic acid (17-ODYA) followed by click 
chemistry-mediated retrieval of labeled substrates promises to simplify transferase assays 
taht can be applied to compound screens. Additionally, because sequences around the 
palmitoylation sites stabilize membrane association and signaling of palmitoylated RAS 
proteins without affecting palmitoylation status itself (70,71), these may also need to be 
taken into account for successful PAT inhibitor development.
Targeting RAS Trafficking by Disrupting Depalmitoylation: APT1/LYPLA1 
Acyl Protein Thioesterases
There has been more progress in the area of inhibiting depalmitoylation, although translating 
the present tool compounds to drugs is also likely to be challenging. Counterintuitive 
although it may seem at first glance, the rationale for inhibiting depalmitoylation of 
palmitoylated RAS proteins is that depalmitoylation on all cellular membranes seems to be 
required for dynamic cycling of NRAS and HRAS among their membrane locations (72). 
This process is facilitated by acyl protein thioesterase 1 (APT1, also known as 
lysophospholipase 1, LYPLA1) and possibly also APT2, which are themselves reversibly S-
acylated (73). The existence of APT in both palmitoylated Golgi-bound and 
nonpalmitoylated cytosolic pools (74) due to autodepalmitoylating activity of APTs (74) 
may explain how cytosolic (nonpalmitoylated) APT can promote cycling of palmitoylatable 
isoforms of RAS proteins to and from membranes, ultimately resulting in enrichment of the 
palmitoylated forms at the PM and Golgi (72,74). These features provide the rationale for 
development of APT1/2 inhibitors as potential anti-RAS agents. The ability of a series of 
beta-lactone-based inhibitors such as palmostatins B and M (derived from the over-the-
counter weight loss drug tetrahydrolipstatin (75,76)) to mislocalize HRAS and NRAS 
proteins to internal membranes (75,76) and to inhibit the proliferation of myeloid progenitor 
cells expressing oncogenic NRAS in treated mice (25) suggests that such inhibitors have the 
potential to disrupt oncogenic NRAS function, although questions remain regarding kinetics 
and target specificity (77). Additional tool compounds such as boron-based APT1/2 
inhibitors have been identified (78). Other recent screens have identified LYPLA1/- and 
LYPLA2-selective inhibitors based on a triazole urea scaffold (79). Interestingly, APTs are 
not the only regulators of RAS depalmitoylation; for example, HRAS becomes 
depalmitoylated following the peptidyl-prolyl isomerase activity of FKBP12 on a proline 
near the palmitoylated cysteines (80). Understanding and optimizing the possible effects of 
such inhibitors may be complicated by the differential dynamics of wild type and oncogenic 
RAS palmitoylation (81), and by the numerous non-RAS substrates of APT1/2/LYPLA1/2 
that also undergo dynamic palmitoylation, including proteins as varied as heterotrimeric G 
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protein alpha subunits, MAGUK scaffolds, Src family tyrosine kinases, nucleoporin and BK 
ion channels (69). Nevertheless, the advent of new labeling technologies and new probes are 
making it possible to better study dynamic palmitoylation (82), which in turn is expected to 
reveal novel paths toward improved inhibitors of this key modification.
Targeting RAS Trafficking by Disrupting Other Modifications: PKC-
mediated Phosphorylation
In addition to CAAX processing and palmitoylation, other post-translational modifications 
of RAS are potentially targetable (1,83). Of these, phosphorylation of KRAS4B on serine 
181, a process that is mutually exclusive with calmodul in binding (84), can alter subcellular 
localization dramatically, displacing the modified GTPase from the PM (50,85), and 
converting KRAS4B from a growth-promoting to a growth-suppressing protein (86). 
Consistent with this, a PKC agonist, bryostatin, slowed the growth of mouse tumors driven 
by oncogenic KRAS4B but not those driven by a phosphorylation-deficient KRAS4B 
mutant (50). It is unclear why, in another study, rodent fibroblasts transformed with 
phosphorylation-deficient KRAS4B12V, 181A failed to produce tumors in nude mice (87), 
leading these investigators to conclude that phosphorylation of KRAS4B is required for 
oncogenesis rather than leading to growth suppression. We have found that crossing p48-Cre 
mice with animals with a phosphorylation-deficient LSL-Kras4B-G12D/S181A double 
knock-in allele produced pancreatic tumors with equal frequency as crossing to mice with a 
phosphomimetic LSL-Kras4B-G12D/S181S allele (unpublished results), arguing strongly 
against a requirement for KRAS4B phosphorylation. Importantly, a recent study (88) 
showed that numerous cancer-associated mutations of PKC isoforms are loss-of-function 
mutations. This finding suggests that these PKCs act as tumor suppressors, consistent with 
the effect of phosphorylating KRAS4B on S181. Regardless of the explanation, although 
bryostatin and analogs have been under preclinical and clinical investigation as anti-cancer 
treatments, are reasonably well tolerated and have anti-tumor activity (89), enthusiasm for 
this approach to anti-KRAS therapy is diminished by low probability of finding a drug that 
stimulates KRAS4B phosphorylation without affecting PKC-mediated activation of other 
signaling molecules that promote tumor growth and/or lead to toxicities.
Targeting RAS Trafficking by Disrupting RAS-Chaperone Interactions
In addition to blocking enzymatic activities regulating RAS membrane interactions, several 
distinct approaches have been taken to disrupting farnesylated RAS binding to chaperones, 
largely with the intent to block oncogenic KRAS4B specifically.
Inhibitors of the Ras-PDE6δ interaction have recently been identified. Deltarasin, at low 
micromolar levels, impaired the accumulation of KRAS4B on the PM and slowed the 
growth in vitro and in vivo of a tumor cell line harboring mutant KRAS (62,90). However, 
the degree of dependence of KRAS on PDE6δ is not yet clear. For example, PDE6d 
knockout mice are viable and fertile (91), whereas knockout of Kras in mice is embryonic 
lethal (92), indicating that KRAS can still function in the absence of PDE6δ. On the other 
hand, the crystal structure of PDE6δ indicates little to no specificity for one farnesylated 
protein over another (63), which may be reflected in the discordant observations of RAS 
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interactions mentioned above. It may also be that, similarly to effective multi-kinase 
inhibitors that were once disparaged as “dirty” drugs, inhibition of multiple farnesylated 
proteins contributes to the salutary effects of deltarasin. Future translation of current PDE6δ 
inhibitors to clinical leads will likely require a better understanding of its chaperone 
specificity (93) and trafficking patterns.
Salirasib, also known as farnesylthiosalicylic acid (FTS), resembles the S-farnesylated 
cysteine on Ras (94,95) and is proposed to compete with it for binding to chaperones such as 
galectins (52,56,96). A small clinical trial showed that salirasib was well tolerated in 
pancreatic cancer patients (97), yet definitive answers as to whether it effectively perturbed 
KRAS function in patients, and can provide clinical benefit, remain to be determined. Like 
the other inhibitors of RAS membrane association, salirasib is not specific for RAS, but also 
inhibits other farnesylated proteins including RHEB and MTOR (1). Larger trials are 
merited, but await a better understanding of salirasib mechanism of action and elucidation of 
tractable biomarkers.
Meanwhile, galectins are also known to modulate RAS nanoclustering and localization 
within defined membrane microdomains (53-56,98), that in turn are regulated by 
phosphatidylserine (98). Thus, perhaps it was not surprising that an unbiased high-content 
screen to observe mislocalization of KRAS4B from PM to endomembranes revealed that 
staurosporine and analogs blocked endosomal recycling of phosphatidylserine and displaced 
KRAS4B from the PM to endosomes where it was degraded (99). Interestingly, fendiline, an 
L-type calcium channel blocker, was also identified as a compound that induced KRAS4B 
mislocalization (100); however, this activity was channel-independent. The third class of 
compound identified in this visual screen was metformin, that also displaced KRAS4B from 
the PM (101). These findings are very exciting because they suggest that unbiased screens 
have the potential to uncover existing drugs that can be repurposed to block KRAS4B 
membrane association. To further identify new regulators of KRAS4B membrane 
association, the Philips lab has designed a genome-wide siRNA screen employing a dual 
luciferase assay that quantitatively reports displacement of KRAS4B from cellular 
membranes (unpublished). We expect that additional roles for still other proteins in 
membrane targeting and/or stabilization have yet to be revealed. As this new information 
adds to the surge in understanding how nascent RAS proteins are delivered to the PM, we 
expect the RAS trafficking pathway to continue to provide a target-rich environment for 
drug discovery.
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Membrane targeting sequences of RAS proteins. Top: the RAS on/off switch that is broken 
in oncogenically mutated RAS and fails to turn off from the active, GTP-bound state that 
interacts with effectors (E) to transmit downstream signals. Since membrane association is 
required for proper effector interaction, interfering with membrane targeting can impair 
signal transmission, like unwiring an electrical switch to prevent it from carrying current. 
Bottom: ribbon diagram of the four RAS proteins, which are 90% similar throughout their G 
domains that bind the guanine nucleotides, regulators and effectors (including switch 
regions SI, SII), but differ greatly at their C-terminal membrane targeting domains. The 
latter consist of a carboxyterminal CAAX tetrapeptide motif (pink boxes) with an invariant 
cysteine that is the site of farnesylation, and an upstream hypervariable region (yellow 
boxes) that include the “second signals” of one (NRAS) or two (HRAS, KRAS4A) 
palmitoylatable cysteines or clusters of positively charged (polybasic) residues (PBR), as 
well as “third signals” comprised of the surrounding residues. KRAS4B has a stretch of six 
contiguous lysines and no palmitoylatable cysteine, whereas KRAS4A has a hybrid motif of 
both a bipartite PBR and a palmitoylatable cysteine. Numbers refer to amino acid residues. 
Asterisks indicate sites of mutational hotspots at G12, G13 and Q61. Dots above the ribbon 
mark each 10 amino acid stretch. Brown bars in the ribbon mark sites of sequence variation. 
P, phosphorylation of KRAS4B at Serine181.
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RAS trafficking pathway. Nascent RAS proteins leaving the polysome are rapidly modified 
by farnesyltransferase (FTase), which attaches a C15 farnesyl isoprenoid lipid to the 
cysteine of the CAAX motif. This provides them sufficient affinity for the endoplasmic 
reticulum (ER), where they are further modified by RAS-converting CAAX endopeptidase 1 
(RCE1)-catalyzed proteolytic removal of the AAX residues, and by reversible 
isoprenylcysteine carboxylmethyltransferase (ICMT)-catalyzed carboxylmethylation of the 
now terminal farnesylated cysteine residue. By preventing the first and obligate step, FTase 
inhibitors (FTIs) prevent all three of these modifications. In the presence of FTIs, KRAS and 
NRAS are alternatively prenylated by geranylgeranyltransferase I (GGTase I), which 
attaches a C20 geranylgeranyl isoprenoid that allows the same subsequent processing steps. 
RAS trafficking to the inner leaflet of the plasma membrane (PM) requires a second 
membrane-targeting element that dictates the pathway it will take to the PM. NRAS and 
HRAS have one or two cysteine residues, respectively, that undergo reversible acylation by 
a Golgi-resident protein acyltransferase (PAT) to promote their trafficking to the PM. Rapid 
deacylation by an acyl protein thioesterase (APT1/2) frees them up to be re-acylated and 
trafficked back to the PM. The nonpalmitoylated pool of APT in the cytosol is the active 
form, and is in dynamic equilibrium with a palmitoylated pool on the Golgi. KRAS4B, 
which has no palmitoylatable cysteine but a stretch of 6 lysines (polybasic region) does not 
go to the Golgi but trafficks to the more directly to the PM, where it binds by virtue of its 
electrostatic charge. KRAS4A, which has a hybrid motif of a palmitoylated cysteine and a 
bifurcated polybasic region, undergoes an intermediate form of trafficking. 
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Phosphodiesterase-6δ (PDE6δ) recognizes the farnesyl isoprenoid and solubilizes 
nonpalmitoylated RAS proteins from any compartment, thereby promoting their availability 
for restoration to the PM; deltarasin blocks this interaction. Not pictured: other chaperone 
proteins that guide the lipidated RAS proteins between and within membrane regions. Each 
enzyme depicted has been a target for drug discovery.
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